MIST - Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Canada NewsWire

MONTREAL and CHARLOTTE, N.C. , Sept. 5, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the H.C. Wainwright 25 ^th Annual Global Investment Conference on Tuesday, September 12, 2023 at 9:00 a.m. ET .

A live webcast of the fireside chat can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com . An archived replay of the fireside chat will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and is in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States . For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
milestone@argotpartners.com

SOURCE Milestone Pharmaceuticals, Inc.

View original content: http://www.newswire.ca/en/releases/archive/September2023/05/c0179.html